Recombinant Human p18 INK4c/CDKN2C protein

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

P18 INK4c also known as CDKN2C is a cyclin-dependent kinase inhibitor that plays an important role in cell cycle regulation. It is a member of the INK4 family and carries a molecular mass of approximately 18 kDa. This protein actively inhibits the activity of CDK4 and CDK6 key kinases that drive the transition from the G1 to S phase in the cell cycle. p18 INK4c is expressed in various tissues with notable expression in the adrenal gland kidney and the nervous system.

Biological function summary

P18 INK4c functions as a regulator by acting as a part of the complex that controls cell proliferation. It ensures that cells do not proceed through the G1/S checkpoint inappropriately maintaining proper cell cycle control. This protein serves as a brake in the cell cycle by binding to CDK4/6 thereby preventing their interaction with D-type cyclins and subsequent cell cycle progression.

Pathways

P18 INK4c is an important component of the retinoblastoma (Rb) pathway as well as the p16INK4a-pRB pathway. These pathways are important for negative regulation of the cell cycle. In these pathways p18 INK4c inhibits CDK4 and CDK6 which are kinases needed to phosphorylate the Rb protein a pivotal step for cell cycle progression. The regulation of these pathways plays a part in processes like cellular senescence and differentiation.

P18 INK4c is associated with various types of cancer including glioma and breast cancer. Alterations in the expression or function of p18 INK4c can lead to unchecked cell proliferation and tumorigenesis. It often interacts with proteins such as CDK4 and CDK6 in these contexts where dysregulation may contribute to the development and progression of the diseases. Understanding p18 INK4c's role could provide insights into potential therapeutic strategies for these cancers.